This study shows HDAC6 inhibition enhances anti-tumoral immune responses and chemosensitivity in myeloid leukemia cells by upregulating RNase T2 and improving chromatin accessibility.

Cell Death and Disease · Mar 7, 2026Peer-reviewedCell Biology

Serum-free differentiation platform for the generation of B lymphocytes and natural killer cells from human CD34+ cord blood progenitors

Rigveda Bhave, Carla‐Johanna Kath, Nadine Rüchel, Eleni Vasileiou, Vera Helena Jepsen, Katharina Raba, Aleksandra A. Pandyra, Ute Fischer, Gesine Kögler

This paper introduces a serum-free co-culture system using human bone marrow stromal cells to differentiate cord blood CD34+ progenitors into B and NK cells, offering a more physiologically relevant model for hematopoiesis research.

Scientific Reports · Dec 18, 2025Peer-reviewedDevelopmental Biology

Linker histone H1-0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape

Vera Helena Jepsen, Andrea Hänel, Daniel J. Picard, Rigveda Bhave, Rebecca Hasselmann, Juha Mehtonen, Julian Schliehe‐Diecks, Carla‐Johanna Kath, Vithusan Suppiyar, Yash Prasad, Katerina Schaal, Jia‐Wey Tu, Nadine Rüchel, Ersen Kameri, Nan Qin, , Ute Fischer

This study identifies H1-0 as a mediator of ETV6::RUNX1-induced quiescence in BCP-ALL preleukemic cells and suggests HDACi treatment as a potential therapeutic approach.

HemaSphere · Apr 1, 2025Peer-reviewedCancer Biology